RecruitingPhase 2NCT05099471
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Christian Buske
- Principal Investigator
- Christian Buske, Prof. Dr.University Hospital Ulm Department of Internal Medicine III
- Intervention
- Venetoclax; Rituximab(drug)
- Enrollment
- 80 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2033
Study locations (11)
- Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany
- Klinikum Chemnitz gGmbH, Chemnitz, Germany
- Klinikverbund Allgaeu gGmbH, Kempten, Germany
- Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Germany
- Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz, Germany
- Dr. Vehling-Kaiser MVZ GmbH, Landshut, Germany
- Kliniken Maria Hilf GmbH Moenchengladbach, Mönchengladbach, Germany
- Haematologie und Onkologie Muenchen-Pasing MVZ GmbH, München, Germany
- Universitaet Muenster, Münster, Germany
- University Hospital Ulm, Ulm, Germany
- Alexandra Hospital, Athens, Greece
Collaborators
Ludwig-Maximilians - University of Munich · Zentrum für Klinische Studien Ulm · AbbVie · Pfizer · University of Ulm · University Hospital Schleswig-Holstein
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05099471 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT06561347Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital
- RECRUITINGPHASE2NCT05190705Loncastuximab Tesirine in WMShayna Sarosiek, MD
- RECRUITINGNCT05093153Spanish Registry of Patients With IgM Monoclonal GammopathiesFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04273139Ibrutinib + Venetoclax in Untreated WMDana-Farber Cancer Institute
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London
- ACTIVE NOT RECRUITINGPHASE1NCT01209871Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaM.D. Anderson Cancer Center